The metabolism of glycerate and aspartate was investigated in perfused rat kidneys. The major pathway active for aspartate metabolism and NH3 production was found to include transamination, and not the purine nucleotide cycle. Pyruvate cycling was identified as a means by which reducing potential is generated in the cytosol for glucose and lactate production from these substrates. Inhibition of mitochondrial pyruvate transport caused an inhibition of glucose production, accumulation of lactate and pyruvate in the perfusate, and a decrease in the [lactate]/[pyruvate] ratio in kidneys perfused with aspartate. These data indicate a role of mitochondrial pyruvate transport in the provision of cytosolic reducing potential. With either aspartate or glycerate, 3-mercaptopicolinic acid (3-MPA) suppressed glucose synthesis and caused accumulation of malate plus fumarate within the kidney. Glucose production from glycerate was much less sensitive to the presence of 3-MPA than was glucose production from aspartate, illustrating a phosphoenolpyruvate carboxykinase (PEPCK)-independent pathway for the cycling of pyruvate. In aspartate-perfused kidneys, the presence of 3-MPA, at concentrations that completely blocked glucose accumulation in the perfusate, did not affect the rate of NH3 production and had only a minor effect on the rate of aspartate uptake. These data allow for an estimation of the rate of pyruvate formation from aspartate of about 1 ,umol/min per kidney under conditions of complete PEPCK inhibition. Thus a PEPCK-independent pathway is operative for amino acid oxidation and pyruvate formation in perfused kidneys. The NADP-linked, but not the NAD-linked, 'malic' enzyme activity of the kidney cortex was found to be sufficient to catalyse this estimated rate of pyruvate formation.
INTRODUCTION
The process of gluconeogenesis requires a cytosolic source of reducing equivalents in the form of NADH for the conversion of oxaloacetate into glucose. With most glucogenic substrates, such as glutamate, serine and alanine, this requirement is met by a 'coupled' oxidation-reduction reaction in which malate efflux from mitochondria provides both the carbon and the reducing potential for glucose synthesis. Although this is also the case with pyruvate as substrate, with higher than physiological concentrations of pyruvate reduction to lactate competes with glucose formation for the available NADH. Malate, which exits from mitochondria and is oxidized for the reduction of pyruvate, ultimately re-enters mitochondria after the cytosolic conversion back into pyruvate (Rognstad & Katz, 1972; Meijer & Williamson, 1974) . This substrate cycle, in which pyruvate carbon enters mitochondria as pyruvate, exits as malate, and is reconverted into pyruvate, functions as an energy-dependent shuttle of reducing equivalents (Berry, 1971; Meijer & Williamson, 1974) . Pyruvate cycling has been shown to occur in liver (Friedman et al., 1971; Rognstad, 1975) and in kidney cortex preparations (Rognstad & Katz, 1972; Janssens et al., 1980) by a variety of isotopic methods.
In the present study, we investigated the means by which reducing potential is generated in the renal-cdrtex cytosol for the conversion of aspartate and other substrates into glucose. We, as have others (NishiitsutsujiUwo et al., 1967; Pitts, 1971) , found aspartate to be glucogenic in perfused rat kidneys. This process was re-investigated in light of subsequent observations that have illustrated the essentially unidirectional nature of the mitochondrial transmembrane transport of aspartate (LaNoue et al., 1974; Tischler et al., 1976 
MATERIALS AND METHODS
Kidneys from male Wistar rats were perfused at a constant pressure of 100 mmHg as described by Scaduto & Davis (1985) . In all cases, donor rats weighed between 280 and 330 g and were deprived of food, but not water, on the afternoon before perfusions.
Metabolites were determined spectrophotometrically by enzymic procedures as previously described (Lee & Davis, 1979) . Glycerate was determined as described for the measurement of serine (Scaduto & Davis, 1985) . Recovery of glycerate and serine as glyoxylate was 92 and 89% respectively. Although this method also includes the determination of pyruvate and threonine, the value is corrected for the pyruvate content and the amount of threonine in the perfusate relative to that of serine or glycerate is insignificant (Scaduto & Davis, 1985) .
At the completion of the 60 min perfusions, kidneys were freeze-clamped with an aluminium clamp precooled with liquid N2, without interruption of perfusate flow. Frozen tissue was stored at -80°C until metabolite extraction. HCIO4 extraction of the frozen tissue and neutralization were as previously described (Scaduto & Davis, 1985) .
For the determination of enzyme activities, the kidney cortex of rats starved overnight was homogenized in ice-cold 225 mM-D-mannitol/75 mM-sucrose/5 mMMops/ 1 mM-dithiothreitol/0.1 mM-EDTA, pH 7.4, by three passes of a Teflon-pestle/glass homogenizer. The homogenate was centrifuged for 5 min at 2000 g, and the supernatant was re-centrifuged for 5 min at 15000 g to pellet the mitochondria, and finally for 60 min at 100QOO gayv to obtain the cytosol preparation. This was used directly after dilution of the protein content to 7.5 mg/ml with the homogenization buffer. The mitochondria were washed by resuspension of the mitochondrial pellet in about 40 ml of homogenization buffer and centrifugation at 8000 g for 10 min. The mitochondria were then resuspended in 1-2 ml of homogenization buffer, transferred to a glass conical test tube, frozen in liquid N2 and stored at -80°C until use. The thawed mitochondria were then disrupted by ultrasonic treatment, as previously described (Lin & Davis, 1974 (Gornall et al., 1949) , with the addition of 0.33% (w/v) incubation for 2 h at room temperature. The contents of the centre well, and two washings of the well with phenethylamine, were transferred to scintillation vials. Reaction rates were calculated from the amount of 14CO2 produced in flasks incubated for 5 and 30 min. The production of 14C02 was linear over this time interval. Mitochondrial NAD-linked 'malic' enzyme activity was measured spectrophotometrically as previously described (Lin & Davis, 1974) . These determinations were done with 30 mM-malate, 1 mM-NAD+, 2 mMarsenite, 2 mM-MnCl2 and 0.1 M-Tris/HC1, pH 7.2. The NADP-linked activity in both preparations was measured spectrophotometrically with 30 mM-2-malate, 1 mM-NADP+, 2 mM-arsenite, 2 mM-MnCl2 and 0.1 MTris/HCl, pH 7.4. Lactate dehydrogenase activity was determined with 2 mM-pyruvate, 2 mM-arsenite, 0.12 mM-NADH and 0.1 M-Tris/HCl, pH 7.2. Glutamate dehydrogenase activity was determined as described by Schmidt (1974) .
Lactate dehydrogenase and glutamate dehydrogenase activities were used to correct for the cross-contamination of protein in these two cellular fractions (Elbers et al., 1974) . The NAD-and NADP-linked activities of 'malic' enzyme(s) were corrected for cross-contamination by assuming that the total activity was localized to these two compartments. For this calculation, the cytosolic NAD-linked activity was corrected to that expected at 30°C, by assuming a Q10 of 2.0. Total activity of 'malic' enzyme in the kidney cortex was estimated by comparison of the corrected activity and that of the appropriate marker enzyme to the total amount of marker enzyme per g of cortex.
The rates of metabolite release and substrate consumption were determined from the amount of metabolite present in the perfusate at the time of sampling. This calculation is based on the metabolite concentrationintheperfusateandthecirculatingvolumeafterappropriate corrections for the changes owing to sampling. The release of some metabolites, such as lactate and pyruvate, was expressed as the amount released during 60 min of perfusion, rather than as a rate, since their release was often non-linear.
All data have been expressed as the mean of replicate experiments +1 S.E.M. Student's t test was used for statistical evaluation of results: P < 0.05 was considered significant.
All chemicals were obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A.), with the following exceptions. D-Glycerate (hemicalcium salt) was a product of Calbiochem (La Jolla, CA, U.S.A.). Just before use, the required amount was converted into the sodium salt by passage through a Dowex 1 x 8 resin column (H+ form) and neutralization of the effluent with NaOH. a-CHC was a product of Aldrich Chemical Co. (Milwaukee, WI, U.S.A.). Hadacidin and 3-MPA were generously given by Dr. Hans Gadebusch of the Merck Institute and Dr. H. L. Saunders of Smith, Kline and French Laboratories respectively. Hadacidin was recrystallized from ethanol/water before use.
RESULTS AND DISCUSSION
Unlike in the perfused rat liver , aspartate is rapidly metabolized to glucose and NH3 by the perfused rat kidney (Nishiitsutsuji-Uwo et al., 1967; Pitts, 1971; Scaduto & Davis, 1985) . Although the major site of renal NH3 production from amino nitrogen is generally considered to be due to glutamate dehydrogenase activity (Tannen, 1978) , the possible contribution of the purine nucleotide cycle, especially during aspartate metabolism, is controversial Strzelecki et al., 1983) . We investigated the source of NH3 production under conditions of renal aspartate metabolism, since this bears considerable significance as to the mechanism for the provision of cytosolic reducing potential for the conversion of this substrate into glucose. Glucose production from aspartate via the purine nucleotide cycle would not require efflux of reducing potential from mitochondria, whereas glucose production via the coupling of cytosolic aspartate aminotransferase and mitochondrial glutamate dehydrogenase would have this requirement.
We reported (Scaduto & Davis, 1985) that 0.3 mmamino-oxyacetate, a transaminase inhibitor (Hopper & Segal, 1962) , inhibited the consumption of aspartate and the release of glutamate, serine and glucose by 89, 87, 88 and 93 % respectively. In addition, the release of aspartate-derived NH3 was suppressed by 89 %. However, if glutamate was the sole substrate, its metabolism was not diminished by the transaminase inhibitor. These results were taken to show that the main, if not the only, route of aspartate metabolism is initiated by transamination, coupled to glutamate dehydrogenase activity. In the present work, these studies were extended in two types of experiments. In the first, kidneys were perfused with either glutamate or aspartate as sole substrate, and approximately half-way through the perfusion period amino-oxyacetate was added. With aspartate as substrate, amino-oxyacetate strongly suppressed NH3 production and virtually abolished net glucose synthesis (Fig. 1) synthesis was affected only marginally, and NH3 release was even increased.
In a second type of experiment, hadacidin (N-formyl-N-hydroxyglycine), an inhibitor of adenylosuccinate synthase (and therefore of the purine nucleotide cycle; Shigeura & Gordon, 1962) , was added to perfusions with aspartate as substrate. In a series of perfusions with 3 mM-aspartate (n = 4), 1 mM-hadacidin (on average) tended slightly to decrease aspartate consumption as well as the release of NH3, glucose and glutamate (results not shown). Since hadacidin is a competitive inhibitor with respect to aspartate, at the concentrations used in these perfusions, it would have been expected (Shigeura & Gordon, 1962) to have inhibited flux through the purine nucleotide cycle (i.e. regeneration of AMP from IMP) >92%, assuming that these concentrations reflect the tissue concentrations. Also, hadacidin was without effect on either the adenine nucleotide pool or the ratios of the individual nucleotides (P > 0.5; results not shown). The possibility remains that hadacidin did not reach its intracellular site of inhibition. This possibility seems to us extremely unlikely, in view of the unique capacity of the kidney to extract virtually all solutes, including cations, anions and neutral molecules such as glucose. Hadacidin inhibits the purine nucleotide cycle specifically in exercising perfused muscle (Aragon & Lowenstein, 1980) . The present data on the specificity ofamino-oxyacetate as an inhibitor of NH3 and glucose production from aspartate, but not from glutamate, together with the lack of effects by hadacidin, provide rather convincing evidence that the pathway of aspartate metabolism involves transamination, and not the purine nucleotide cycle. This conclusion is supported by the report by Strzelecki etal. (1983) , who used a completely independent experimental approach to this question. Provision of cytosolic reducing potential for the synthesis of glucose and lactate Since aspartate is unable directly to enter energized mitochondria (LaNoue et al., 1974; Tischler et al., 1976) , glucose production from aspartate via the cytosolic aspartate aminotransferase represents a pathway in which carbon transfer from aspartate to glucose is completely a cytosolic process. This pathway is essentially gluconeogenesis from cytosolic oxaloacetate, but the NADH required for this reductive process must come from mitochondrial substrate oxidations.
One source of NADH for this conversion was identified as serine production from glycolytic intermediates (Scaduto & Davis, 1985) . Serine synthesis from aspartate (or glutamate) is the result of the activity of eitherthe' phosphorylated 'and/or' non-phosphorylated' pathway(s). Since both pathways involve a cytosolic NAD-linked oxidation, this process can be coupled to glucose synthesis through redox reactions. Such a pathway is illustrated in Scheme 1, assuming that serine is synthesized via the 'phosphorylated' pathway, which is the more likely of the two (Scaduto & Davis, 1985) . As shown, the stoichiometry of this couple must be 2 equivalents of serine synthesized per equivalent of glucose for serine synthesis to provide sufficient reducing potential for the quantity of glucose formed from aspartate. However, kidneys perfused with 3 mMaspartate released serine and glucose at approximately equal rates (Scaduto & Davis, 1985 synthesis at most could have provided half of the reducing potential for the observed rate of glucose production. Considering that some of the glucose released by the cortex is oxidized in other portions of the kidney (Hems & Gaja, 1972; Scaduto & Davis, 1985) , this value is less than one-half. Cycling of pyruvate through vectorial movements across the mitochondrial membrane and involving the following transformations constitutes an energy-dependent translocation of reducing equivalents from mitochondria to cytosol: cytosolic pyruvate mitochondrial pyruvate -* mitochondrial oxaloacetate mitochondrial malate -. cytosolic malate -÷ cytosolic pyruvate. Studies with perfused liver and isolated hepatocytes have provided evidence that such a cycle is operative in the synthesis of glucose and lactate from pyruvate (e.g. Friedman et al., 1971; Rognstad, 1975; Mapes & Harris, 1976) . This concept has been extended in studies with kidney tubule fragments oxidizing pyruvate (Saggerson, 1978 (Table 1) . As a first consideration it would not necessarily be predicted that octanoate would restore gluconeogenesis from glycerate. However, the probable explanation is as follows: oc-CHC elevated the concentration of pyruvate more than 10-fold and, at the concentration used, a-CHC does not suppress pyruvate transport completely (Vaartjes et al., 1979; Rognstad, 1983) . Therefore, pyruvate uptake was partially restored when its concentration was greatly elevated. That this process was still partially uncompensated is evidenced by the finding that the [lactate]/[pyruvate] ratio was not restored to the uninhibited value. It has been shown that, when pyruvate is in the physiological concentration range, octanoate stimulates carboxylation of pyruvate many-fold (Davis-van Thienen & Davis, 1981) . This would tend to pull the pyruvate cycling process.
For gluconeogenesis from malate, pyruvate recycling is not necessary for cytoplasmic NADH production. This is documented by the lack of effect of a-CHC on the [lactate]/[pyruvate] ratio (Table 1) . Since the energy requirements to sustain the kidney must now be provided by malate-derived pyruvate, it is not surprising that inhibition of pyruvate entry into mitochondria would suppress gluconeogenesis from malate.
Glutamate was also used as sole substrate to evaluate the effects of a-CHC on its metabolism, since there is no need for pyruvate cycling to generate cytoplasmic reducing equivalents from this substrate for gluconeogenesis, nor is pyruvate entry into mitochondria required for energy (ATP) production. Glucose synthesis was only marginally suppressed by ac-CHC, the [lactate]/ [pyruvate] ratio was sustained in the physiological range, but there was a net increase in accumulation of lactate plus pyruvate. Therefore gluconeogenesis from glutamate and maintenance of cytoplasmic redox state are principally independent of pyruvate cycling (Table 1) .
More direct evidence for the operation of pyruvate cycling during the metabolism of glycerate was obtained through an investigation of the effects caused by inhibition of PEPCK by 3-MPA. As shown in Table 2 indicating a role for PEPCK in the shuttling of reducing potential from the mitochondria. Evidently, the reaction catalysed by PEPCK, a step that is not required for the direct conversion of glycerate carbon into glucose, normally functions as part of a pyruvate cycle. However, its activity does not appear to be obligatory for the shuttling process, since synthesis of glucose and lactate is not strongly suppressed by 3-MPA. This concentration of 3-MPA is sufficient to inhibit glucose production from 3 mM-aspartate by about 94% (Scaduto & Davis, 1985) .
Thus these data are of considerable importance, since they illustrate a PEPCK-independent mechanism for the shuttling of reducing potential. The operation of a PEPCK-independent pathway for formation of pyruvate can be estimated by calculating the rate of aspartate oxidation from the difference in aspartate consumption and the synthesis of all products of its metabolism. In perfusions in which PEPCK flux is completely blocked (1.5 mM-3-MPA; glucose and serine synthesis blocked, without affecting NH3 production), the calculated residual rate of PEPCK-independent oxidation ofaspartate (and therefore pyruvate oxidation) was 1.07 + 0.10,umol/min per kidney, and NH3 production was the same as aspartate oxidation (1. malate, and the latter transported into the cytosol. As discussed above, the cytoplasmic malate can, in principle, be recycled back to pyruvate by at least three mechanisms, with the coupled generation of NAD(P)H. The PEPCK-dependent pathway is clearly functional, but, in addition, there is a PEPCK-independent pathway. This leaves the 'malic' enzymes and oxaloacetate decarboxylase as the remaining known possibilities for the latter. A weak oxaloacetate decarboxylase has been shown to occur in both rat kidney and liver mitochondria (Wojtczak & Walajtys, 1974) , but this location is ofno direct function in generating cytoplasmic NAD+. Furthermore, the high Km for oxaloacetate (>0.5 mM) probably negates its function in this pathway. Finally, we have demonstrated the presence of both NAD-and NADP-linked 'malic' enzyme activities. For the NAD-linked enzyme, the total activity is too low to account for the calculated PEPCK-independent cycling of pyruvate. Furthermore, most of this activity was found to be of mitochondrial origin. Although this activity could function in recycling pyruvate, it would not be functional in generating cytoplasmic NADH. NADP-linked 'malic' enzyme activity in kidney cortex has been previously reported (Alleyne et al., 1978; Watford et al., 1980) . Our own estimate of this activity was calculated to be sufficient to account for aspartate oxidation in the presence of 3-MPA. However, if this activity is also involved in pyruvate cycling linked to glucogenesis, this implies a substrate-mediated transhydrogenation from NADPH to NAD+.
In contrast with glucogenesis from glycerate, glucose synthesis from aspartate requires carbon flux through PEPCK (Scheme 2). We have also shown a PEPCKindependent pathway ofpyruvate cycling from aspartate. A bifurcated pathway of aspartate carbon is therefore inferred: (a) recycling of aspartate-derived pyruvate to provide cytoplasmic NADH, coupled to (b) direct conversion of aspartate carbon into glucose precursors, which is not necessarily linked to pyruvate formation via pyruvate kinase.
In the present context it is important to cite the earlier work on renal gluconeogenesis from pyruvate (Saggerson, 1978) or from 2-oxoglutarate or glutamine (Watford et al., 1980) . Saggerson (1978) reached the guarded conclusion that some of the supply of reducing equivalents for glucose and lactate formation from pyruvate is provided by a pathway not involving cycling through pyruvate carboxylase, PEPCK and pyruvate kinase ('malic' enzyme?). In like manner, Watford et al. (1980) noted that inhibition of renal gluconeogenesis from glutamine or 2-oxoglutarate was without effect on complete oxidation of these substrates to CO2 (in some species). On the basis of this and other evidence, these workers implicated 'malic' enzyme in this cycling process.
Finally, it has been reported that liver cells form lactate from citrate-cycle intermediates under certain conditions, and that this process is strongly stimulated by ethanol (see, e.g., Hensgens et al., 1978; Davis & Baugh, 1985) . 3-MPA blocked gluconeogenesis, but further increased lactate accumulation. Once again, these studies implicate, but do not prove, involvement of 'malic' enzymes in this cycling process.
The accumulated evidence from our and other laboratories has clearly established that citrate-cycle intermediates can be converted by gluconeogenic tissues (liver and kidney cortex) into pyruvate by pathway(s) independent of the PEPCK-and pyruvate kinase-linked process. Although the exact identity of this reaction(s) remains to be established, this flux would be expected to play an important role in the homeostasis and substrate disposition in these multi-functional tissues. We propose that this pathway becomes an important by-pass, allowing for the complete oxidation of citrate-cycle intermediates and their precursors under conditions in which gluconeogenesis is not required. In a similar manner, we have proposed previously (Davis et al., 1972; Davis & Bremer, 1973; Lin & Davis, 1974 ) the mitochondrial NAD-linked 'malic' enzyme as a mechanism for removal of excessively generated cycle intermediates in muscle.
